Krystal Biotech, INC

Krystal Biotech announced robust second quarter 2026 financial and operating results, highlighted by significant global revenue growth for VYJUVEK and promising updates across its diverse clinical pipeline.

Krystal Biotech disclosed positive single-patient data for its investigational gene therapy KB801, showing complete closure of a persistent corneal epithelial defect.

Krystal Biotech reported robust first-quarter 2026 financial and operating results, driven by significant global revenue growth for its VYJUVEK treatment and progress across its pipeline programs.

Krystal Biotech reported robust financial results for Q4 and full year 2025, driven by strong VYJUVEK revenue and significant pipeline advancements.

Krystal Biotech announced preliminary unaudited 2025 financial results, including strong VYJUVEK net product revenue, and detailed its rare disease strategic vision and 2026 corporate objectives.

Krystal Biotech announces successful wild-type CFTR delivery and expression in cystic fibrosis patients' lungs from its CORAL-1 study, advancing its mutation-agnostic gene therapy.

Krystal Biotech announces significant revenue growth driven by VYJUVEK sales and advances in its diverse gene therapy pipeline.

Krystal Biotech announces a 32% year-over-year increase in product revenue for Q1 2026, driven by strong VYJUVEK sales, and provides updates on its diverse gene therapy pipeline.

Krystal Biotech reports significant revenue growth and net income for Q3 and nine months ended September 30, 2025, driven by strong VYJUVEK sales and a deferred tax asset release.

Krystal Biotech reports strong Q2 2025 financial results, driven by VYJUVEK sales and recent global regulatory approvals in Europe and Japan.

Krystal Biotech's Q1 2025 revenue surged to $88.2 million, driven by increased sales of VYJUVEK after its FDA and European Commission approvals.

Krystal Biotech's Q3 2024 results show significant revenue growth driven by VYJUVEK sales, reaching $83.8 million for the quarter.

Krystal Biotech's 2025 annual report highlights significant revenue growth from its gene therapy VYJUVEK, expanded global approvals, and positive clinical progress across its pipeline, while navigating increased operating expenses.

Krystal Biotech's 2024 10-K filing highlights the successful commercial launch of VYJUVEK, ongoing clinical trials, and strategic expansion initiatives.

Krystal Biotech's FY2023 results highlight the successful commercial launch of VYJUVEK, the first FDA-approved treatment for dystrophic epidermolysis bullosa (DEB), and continued progress in its gene therapy pipeline.

Krystal Biotech's EVP, General Counsel, Thomas John Charles, executed a Rule 10b5-1 trading plan, selling 1,000 shares of common stock.

Suma Krishnan, President of R&D at Krystal Biotech, sold 25,178 shares of common stock on June 4, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Krystal Biotech CEO Krish S. Krishnan sold 25,000 shares of common stock on June 4, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

John C. Thomas, EVP and General Counsel of Krystal Biotech, sold 642 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Krystal Biotech's President of R&D, Suma Krishnan, sold 25,000 shares of common stock for over $6.5 million under a pre-arranged 10b5-1 trading plan.

Krystal Biotech's President and CEO, Krish S. Krishnan, sold 25,928 shares of common stock on March 4, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 15, 2026, to address key corporate governance and compensation matters.

Krystal Biotech, Inc. has filed a definitive proxy statement with the SEC.

Krystal Biotech's 2025 annual meeting will address director elections, auditor ratification, and executive compensation.

Krystal Biotech, Inc. has filed a definitive proxy statement with the SEC.

Krystal Biotech will hold its 2024 annual meeting of stockholders virtually on May 17, 2024, to vote on director elections, auditor ratification, and executive compensation.

Krish S. Krishnan and Suma M. Krishnan jointly report beneficial ownership of 3,388,283 shares, representing 11.5% of Krystal Biotech, Inc. common stock.

Vanguard Portfolio Management has reported beneficial ownership of 5.05% of Krystal Biotech Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Krystal Biotech Inc. common stock following an internal realignment.

State Street Corporation has reported a passive beneficial ownership of 4.4% of Krystal Biotech Inc.'s common stock as of December 31, 2024.